rp-HPLC fractionation of muscle proteins as an initial step for the identification of autoantigens in inclusion body myositis (IBM)

Verschuuren, Jan J.; Geleijns, C.P.W.; Noort, Johannes M. van; Heer, Emile de; Duinen, Sjoerd G. van; Hintzen, Rogier Q.; Badrising, Umesh A.; Wintzen, A.R.

doi:10.1016/s0960-8966(97)87314-2

Cited by 3 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Early diagnostic criteria emphasized the histopathological changes in IBM muscle, 3 but more recent criteria include typical clinical signs and symptoms. [4][5][6][7] Although many studies on IBM patient cohorts include epidemiological aspects, there are only approximately a dozen population-based investigations on IBM prevalence, and large differences ranging from 0.68 patients with IBM per million inhabitants in Turkey to 50.5 per million inhabitants in South Australia, both studies using local criteria, 8,9 and 182 per million inhabitants over 50 years old in Minnesota, in the United States, using the 2011 European Neuromuscular Centre (ENMC) criteria, have been described. 4,10 The effect of IBM on survival is unclear and although earlier studies have not shown any impact of IBM on life expectancy, [11][12][13] three more recent studies report a reduced survival rate.…”

mentioning

confidence: 99%

Epidemiology, Survival, and Clinical Characteristics of Inclusion Body Myositis

Lindgren

Pullerits

Lindberg

et al. 2022

Annals of Neurology

View full text Add to dashboard Cite

Objective: We performed a population-based study on inclusion body myositis with the primary aims to define the prevalence, survival rate, and incidence, and to investigate the symptom profiles associated with disease duration and sex over a 33-year period. Methods: Patients diagnosed between 1985 and 2017 in Region Västra Götaland, Sweden, were identified according to the European Neuromuscular Centre diagnostic criteria from 2011. Results: We identified 128 patients, 89 men and 39 women, with the strict clinicopathological definition of inclusion body myositis. The prevalence was 32 per million inhabitants, 19 per million women and 45 per million men, by December 31, 2017. Mean incidence was 2.5 per million inhabitants and year. Mean age at symptom onset was 64.4 years with quadriceps weakness being the most common presenting symptom followed by finger flexor weakness. Dysphagia was a common presenting symptom being more frequent in women (23%) than men (10%) and was during the disease course reported in 74% of men and 84% of women. Seventy-three patients were deceased, with a mean survival of 14 years from symptom onset. Survival rates from both diagnosis date and symptom onset were decreased compared to the matched population. Twenty-one percent of the patients had an additional autoimmune disease. A cross-sectional analysis of autoantibodies in 50 patients and 28 matched controls showed autoantibodies to cytosolic 5 0 -nucleotidase 1A in 40% of the patients and 3.6% of controls. Interpretation: Inclusion body myositis is an autoimmune disease with decreased survival rate and with marked sex differences in both prevalence and clinical manifestations.

show abstract

mentioning

confidence: 99%

Epidemiology, Survival, and Clinical Characteristics of Inclusion Body Myositis

Lindgren

Pullerits

Lindberg

et al. 2022

Annals of Neurology

View full text Add to dashboard Cite

show abstract

“…Diagnosis is established based on a combination of clinical features and muscle biopsy findings. Several diagnostic criteria have been published, all requiring a combination of clinical and histopathological features [13–23]. All included diagnostic categories share very high specificity of more than 97% with variable sensitivity ranging from 11% to 84% [23].…”

Section: Diagnosis and Diagnostic Challengesmentioning

confidence: 99%

Exploring challenges in the management and treatment of inclusion body myositis

Skolka,

Naddaf

2023

Current Opinion in Rheumatology

View full text Add to dashboard Cite

Purpose of review This review provides an overview of the management and treatment landscape of inclusion body myositis (IBM), while highlighting the current challenges and future directions. Recent findings IBM is a slowly progressive myopathy that predominantly affects patients over the age of 40, leading to increased morbidity and mortality. Unfortunately, a definitive cure for IBM remains elusive. Various clinical trials targeting inflammatory and some of the noninflammatory pathways have failed. The search for effective disease-modifying treatments faces numerous hurdles including variability in presentation, diagnostic challenges, poor understanding of pathogenesis, scarcity of disease models, a lack of validated outcome measures, and challenges related to clinical trial design. Close monitoring of swallowing and respiratory function, adapting an exercise routine, and addressing mobility issues are the mainstay of management at this time. Summary Patients with IBM and the medical community face numerous challenges in terms of clinical manifestations, diagnosis, and treatment. Overcoming these challenges necessitates the adoption of innovative research strategies. By understanding and addressing these hurdles, researchers and medical professionals can strive towards improving the management and treatment of IBM enhancing the quality of life for affected individuals.

show abstract

Sample preparation for peptides and proteins in biological matrices prior to liquid chromatography and capillary zone electrophoresis

2005

View full text Add to dashboard Cite

The determination of peptides and proteins in a biological matrix normally includes a sample-preparation step to obtain a sample that can be injected into a separation system in such a way that peptides and proteins of interest can be determined qualitatively and/or quantitatively. This can be a rather challenging, labourious and/or time-consuming process. The extract obtained after sample preparation is further separated using a compatible separation system. Liquid chromatography (LC) is the generally applied technique for this purpose, but capillary zone electrophoresis (CZE) is an alternative, providing fast, versatile and efficient separations. In this review, the recent developments in the combination of sample-preparation procedures with LC and CZE, for the determination of peptides and proteins, will be discussed. Emphasis will be on purification from and determination in complex biological matrices (plasma, cell lysates, etc.) of these compounds and little attention will be paid to the proteomics area. Additional focus will be put on sample-preparation conditions, which can be 'hard' or 'soft', and on selectivity issues. Selectivity issues will be addressed in combination with the used separation technique and a comparison between LC and CZE will be made.

show abstract

rp-HPLC fractionation of muscle proteins as an initial step for the identification of autoantigens in inclusion body myositis (IBM)

Cited by 3 publications

References 0 publications

Epidemiology, Survival, and Clinical Characteristics of Inclusion Body Myositis

Epidemiology, Survival, and Clinical Characteristics of Inclusion Body Myositis

Exploring challenges in the management and treatment of inclusion body myositis

Sample preparation for peptides and proteins in biological matrices prior to liquid chromatography and capillary zone electrophoresis

Contact Info

Product

Resources

About